I agree that this site is using cookies. You can find further informations here.
X
Vigna, Ernesto
51  results:
OpenAccess-fulltext X
Search for persons X
?
1

Azacitidine Post-Remission Therapy for Elderly Patients wit..:

Oliva, Esther Natalie ; Candoni, Anna ; Salutari, Prassede...
info:eu-repo/semantics/altIdentifier/wos/WOS:000991562000001.  , 2023
Link: https://hdl.handle.net/1..
 
?
2

Elotuzumab plus pomalidomide and dexamethasone in relapsed/..:

Gentile, Massimo ; Vigna, Ernesto ; Palmieri, Salvatore...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10772491/.  , 2023
Link: http://www.ncbi.nlm.nih...
 
?
3

Safe and Effective Administration of Caplacizumab in COVID-..:

Bruzzese, Antonella ; Vigna, Ernesto ; Terzi, Dario...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10366750/.  , 2023
Link: http://www.ncbi.nlm.nih...
 
?
4

Elotuzumab plus lenalidomide and dexamethasone in relapsed/..:

Bruzzese, Antonella ; Derudas, Daniele ; Galli, Monica...
info:eu-repo/semantics/altIdentifier/pmid/35608183.  , 2022
Link: http://hdl.handle.net/24..
 
?
5

Cerebral pheohyphomycosis due to curvularia species:

Bova, Carlo ; Vigna, Ernesto ; Gentile, Massimo.
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8749271/.  , 2022
Link: http://www.ncbi.nlm.nih...
 
?
6

Survival Risk Scores for Real-Life Relapsed/Refractory Mult..:

Morabito, Fortunato ; Zamagni, Elena ; Conticello, Concetta...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9341470/.  , 2022
Link: http://www.ncbi.nlm.nih...
 
?
7

Survival Risk Scores for Real-Life Relapsed/Refractory Mult..:

Morabito, Fortunato ; Zamagni, Elena ; Conticello, Concetta...
info:eu-repo/semantics/altIdentifier/pmid/35924160.  , 2022
Link: http://hdl.handle.net/10..
 
?
8

Treatment of Lenalidomide Exposed or Refractory Multiple My..:

Botta, Cirino ; Martino, Enrica Antonia ; Conticello, Concetta...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8079718/.  , 2021
Link: http://www.ncbi.nlm.nih...
 
?
9

Adjusted comparison between elotuzumab and carfilzomib in c..:

Morabito, Fortunato ; Zamagni, Elena ; Conticello, Concetta...
info:eu-repo/semantics/altIdentifier/pmid/34716957.  , 2021
Link: http://hdl.handle.net/24..
 
?
10

Spotlight on Melphalan Flufenamide: An Up-and-Coming Therap..:

Morabito, Fortunato ; Tripepi, Giovanni ; Martino, Enrica Antonia...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8275138/.  , 2021
Link: http://www.ncbi.nlm.nih...
 
?
11

Validation of the alternative international prognostic scor..:

Morabito, Fortunato ; Tripepi, Giovanni ; Vigna, Ernesto...
info:eu-repo/semantics/altIdentifier/pmid/33662164.  , 2021
Link: http://hdl.handle.net/24..
 
?
12

Spotlight on Melphalan Flufenamide: An Up-and-Coming Therap..:

Morabito, Fortunato ; Tripepi, Giovanni ; Martino, Enrica Antonia...
info:eu-repo/semantics/altIdentifier/doi/10.2147/DDDT.S295215.  , 2021
Link: https://www.dovepress.co..
 
?
13

TP53 disruption as a risk factor in the era of targeted the..:

Morabito, Fortunato ; Del Poeta, Giovanni ; Mauro, Francesca Romana...
info:eu-repo/semantics/altIdentifier/pmid/33989438.  , 2021
Link: http://hdl.handle.net/24..
 
?
14

Elotuzumab, lenalidomide, and dexamethasone as salvage ther..:

Gentile, Massimo ; Specchia, Giorgina ; Derudas, Daniele...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776255/.  , 2021
Link: http://www.ncbi.nlm.nih...
 
?
15

Effectiveness of ibrutinib as first-line therapy for chroni..:

Morabito, Fortunato ; Tripepi, Giovanni ; Del Poeta, Giovanni...
info:eu-repo/semantics/altIdentifier/pmid/33878220.  , 2021
Link: http://hdl.handle.net/24..
 
1-15